The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial
- PMID: 7826293
- DOI: 10.1001/archopht.1995.01100010038019
The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial
Abstract
Objective: To determine the magnitude of the decrease in the risk of retinopathy progression observed with intensive treatment and its relationship to baseline retinopathy severity and duration of follow-up.
Design: Randomized clinical trial, with 3 to 9 years of follow-up.
Setting and patients: Between 1983 and 1989, 29 centers enrolled 1441 patients with insulin-dependent diabetes mellitus aged 13 to 39 years, including 726 patients with no retinopathy and a duration of diabetes of 1 to 5 years (primary prevention cohort) and 715 patients with very mild to moderate nonproliferative diabetic retinopathy and a duration of diabetes of 1 to 15 years (secondary intervention cohort). Ninety-five percent of all scheduled examinations were completed.
Interventions: Intensive treatment consisted of the administration of insulin at least three times a day by injection or pump, with doses adjusted based on self-blood glucose monitoring and with the goal of normoglycemia. Conventional treatment consisted of one or two daily insulin injections.
Outcome measures: Change between baseline and follow-up visits on the Early Treatment Diabetic Retinopathy Study retinopathy severity scale, assessed with masked gradings of stereoscopic color fundus photographs obtained every 6 months.
Results: Cumulative 8.5-year rates of retinopathy progression by three or more steps at two consecutive visits were 54.1% with conventional treatment and 11.5% with intensive treatment in the primary prevention cohort and 49.2% and 17.1% in the secondary intervention cohort. At the 6- and 12-month visits, a small adverse effect of intensive treatment was noted ("early worsening"), followed by a beneficial effect that increased in magnitude with time. Beyond 3.5 years of follow-up, the risk of progression was five or more times lower with intensive treatment than with conventional treatment. Once progression occurred, subsequent recovery was at least two times more likely with intensive treatment than with conventional treatment. Treatment effects were similar in all baseline retinopathy severity subgroups.
Conclusions: The results of the Diabetes Control and Complications Trial strongly support the recommendation that most patients with insulin-dependent diabetes mellitus use intensive treatment, aiming for levels of glycemia as close to the nondiabetic range as is safely possible.
Similar articles
-
Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.Arch Ophthalmol. 1998 Jul;116(7):874-86. doi: 10.1001/archopht.116.7.874. Arch Ophthalmol. 1998. PMID: 9682700 Clinical Trial.
-
Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.Ophthalmology. 1995 Apr;102(4):647-61. doi: 10.1016/s0161-6420(95)30973-6. Ophthalmology. 1995. PMID: 7724182 Clinical Trial.
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401. N Engl J Med. 1993. PMID: 8366922 Clinical Trial.
-
Retinopathy in patients with type 1 diabetes 4 years after intensive therapy.Arch Ophthalmol. 2000 Jul;118(7):984-5. Arch Ophthalmol. 2000. PMID: 10910526 Review. No abstract available.
-
Management of Patients with Newly Diagnosed Diabetic Mellitus: Ophthalmologic Outcomes in Intensive versus Conventional Glycemic Control.Clin Ophthalmol. 2021 Jun 25;15:2767-2785. doi: 10.2147/OPTH.S301317. eCollection 2021. Clin Ophthalmol. 2021. PMID: 34234400 Free PMC article. Review.
Cited by
-
2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.Diabetes Metab J. 2024 Jul;48(4):546-708. doi: 10.4093/dmj.2024.0249. Epub 2024 Jul 26. Diabetes Metab J. 2024. PMID: 39091005 Free PMC article. No abstract available.
-
Use of VESsel GENeration with Optical Coherence Tomography Angiography and Fluorescein Angiography for Detection and Quantification of Vascular Changes in Mild and Moderate Diabetic Retinopathy.Life (Basel). 2024 Jul 18;14(7):893. doi: 10.3390/life14070893. Life (Basel). 2024. PMID: 39063646 Free PMC article.
-
Intravitreal DEX Implant for the Treatment of Diabetic Macular Edema: A Review of National Consensus.Pharmaceutics. 2023 Oct 13;15(10):2461. doi: 10.3390/pharmaceutics15102461. Pharmaceutics. 2023. PMID: 37896220 Free PMC article. Review.
-
ƩexcessA1C index, the sum of yearly excess HbA1c values during the total period of diabetes, may have the potential to predict retinopathy by a linear regression setting regardless of duration in type 1 diabetes: a subgroup analysis of DCCT/EDIC data.Diabetol Int. 2023 Aug 10;14(4):440-444. doi: 10.1007/s13340-023-00654-w. eCollection 2023 Oct. Diabetol Int. 2023. PMID: 37781457 Free PMC article.
-
Diabetic Macular Oedema Guidelines: An Australian Perspective.J Ophthalmol. 2023 Feb 14;2023:6329819. doi: 10.1155/2023/6329819. eCollection 2023. J Ophthalmol. 2023. PMID: 36824442 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical